---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-010087"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2024-02-02T23:59:59+00:00"
generated_at: "2026-06-06T09:58:39.886605+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# NRx Pharmaceuticals transfers listing to Nasdaq Capital Market effective Jan 19, 2024

## Summary
- Nasdaq approved transfer from Global Market to Capital Market; effective Jan 19, 2024.
- Company had previously received extension until April 16, 2024 to regain compliance.
- Transfer is a condition of the extension; avoids immediate delisting.
- Listing on Capital Market subject to continued compliance with rules.

## SEC filing metadata
- accession: 0001104659-24-010087
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2024-02-02T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000110465924010087/0001104659-24-010087-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000110465924010087/tm245109d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-010087
- JSON: https://secwatch.observer/filing/0001104659-24-010087.json
- Plain text: https://secwatch.observer/filing/0001104659-24-010087.txt

## Key facts
- Listing & Compliance Notices
  NRX Pharmaceuticals, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1)
  source text: February 1, 2024, Nasdaq informed the Company that it had approved the Company’s application to transfer its listing and that the Company’s securities were transferred to The Nasdaq Capital Market at the opening of business on January 19, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NRX PHARMACEUTICALS, INC. Date: February 2, 2024 By: /s/ Stephen Willard Name: Stephen Willard Title: Acting General Counsel
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000110465924010087/0001104659-24-010087-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.